Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: irinotecan-eluting beads, hepatic artery embolization; Combination Product · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Childhood Obesity
Interventions: Brighter Bites, CATCH; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 7 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colon Cancer
Interventions: 70g of fully digestible starch amylopectin corn starch, Resistant starch; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Anchorage, Alaska • Pittsburgh, Pennsylvania

Conditions: Non-alcoholic Fatty Liver Disease, Diabetes
Interventions: Dietary intervention (calorie restricted diet); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Vallejo, California

Conditions: Social Phobia, Body Dysmorphic Disorder
Interventions: Cognitive-behavioral therapy; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Actinic Keratoses
Interventions: BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more

Conditions: Pancreatic Neoplasm, Neoplasm Metastasis
Interventions: S-1, 5-Fluorouracil; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Obsessive-compulsive Disorders and Symptoms in Children
Interventions: Cognitive Behavioral Therapy, Community Referral as appropriate; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 6 Years to 14 Years
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: Lymphoma
Interventions: Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
Interventions: ATP128, BI 754091, VSV-GP128; Drug
Lead sponsor: Amal Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Lung Cancer, Depression, Physical Activity, Quality of Life, Pain, Lung Cancer Symptoms
Interventions: Exercise Intervention, Survey Administration, Quality-of-Life Assessment; Behavioral · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Post Hematopoietic Stem Cell Transplantation
Interventions: Data Collection; Other
Lead sponsor: Karen Wood; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pancreatic Fluid Collections, Biliary Obstruction, Pancreatic Duct Obstruction, Chronic Pancreatitis, Pancreatic Cancer Non-resectable
Interventions: EUS-guided intervention using the RIVOS™ EUS access device; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Sensitivity
Interventions: Intervention 1, Intervention 2, Intervention 3, Intervention 4 (sham); Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Migraine
Interventions: topiramate, frovatriptan; Drug
Lead sponsor: Clinvest; Individual
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Oviedo, Florida • Springfield, Missouri

Conditions: Breast Cancer
Interventions: Pain Coping Skills Training (PCST); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 55 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Overweight and Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Eldery People, Cognitive Decline, Memory Decline, DHA CNS Delivery
Interventions: LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta); Dietary Supplement
Lead sponsor: University of Cincinnati; Other
Eligibility: 55 Years to 82 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Opioid-Related Disorders
Interventions: Naltrexone; Drug
Lead sponsor: Yale University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1998
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prescription Opioid Dependence
Interventions: buprenorphine taper followed by naltrexone maintenance, Behavioral therapy; Drug · Behavioral
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Melanoma
Interventions: dacarbazine plus Genasense, dacarbazine plus placebo; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more

Conditions: Anemia
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Observation unit care, coupled with cardiac MRI; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Borderline Personality Disorder
Interventions: Lamotrigine, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Belmont, Massachusetts

Search by objective public record fields.

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

Brighter Bites - Access, Continuity and Education With Fruits and Vegetables

Fiber to Reduce Colon Cancer in Alaska Native People

De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease

Brain Correlates of Self-Focused Processing

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

Task Control Circuit Targets for Obsessive Compulsive Behaviors in Children

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Exercise Program Among Lung Cancer Dyads

Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation

EUS Procedures Using RIVOS™ EUS Access Device

Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

Behavioral Pain Intervention for Older Cancer Patients

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia

Neurobiology of Opioid Dependence: 4 - 4

Effective Treatment for Prescription Opioid Abuse

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Etiology of Anemia

Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain

Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder